You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 292 No. 1, July 7, 2004 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Nutritional and Metabolic Disorders
 •Lipids and Lipid Disorders
 •Cardiovascular System
 •Randomized Controlled Trial
 •Cardiovascular Disease/ Myocardial Infarction
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Aggressive Lipid-Lowering Therapy and Regression of Coronary Atheroma

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: We have 2 concerns about the study by Dr Nissen and colleagues.1 First, we were puzzled by why the authors did not compare 2 dosages of the same statin. Not only would this design have been in accordance with the ongoing Treating to New Targets study, it also could supply pathophysiological data for the possible differences in the primary end point in that study.2 We are concerned that the results may be oversimplified by suggesting superiority of atorvastatin over pravastatin. Had the authors used the same drug in both groups, attention could have been focused toward intensive vs moderate lipid lowering.

Second, we are concerned that the ultrasound images may be misinterpreted. For instance, in their figure 3, Nissen et al provided an intravascular image showing a substantial reduction of 43% in atheroma area. Such a result, in fact, was atypical for the entire group of patients . . . [Full Text of this Article]

Pim van der Harst, MD
p.van.der.harst@thorax.azg.nl

Wiek H. van Gilst, PhD; Felix Zijlstra, MD, PhD
University Hospital Groningen
Groningen, the Netherlands



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Aggressive Lipid-Lowering Therapy and Regression of Coronary Atheroma
Uffe Ravnskov and Morley C. Sutter
JAMA. 2004;292(1):38.
EXTRACT | FULL TEXT  

Aggressive Lipid-Lowering Therapy and Regression of Coronary Atheroma
Paul J. Rosch
JAMA. 2004;292(1):38-39.
EXTRACT | FULL TEXT  

Aggressive Lipid-Lowering Therapy and Regression of Coronary Atheroma
Kavitha Rajaram
JAMA. 2004;292(1):39.
EXTRACT | FULL TEXT  

Aggressive Lipid-Lowering Therapy and Regression of Coronary Atheroma—Reply
Steven Nissen and For the REVERSAL Investigators
JAMA. 2004;292(1):39-40.
EXTRACT | FULL TEXT  

Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis: A Randomized Controlled Trial
Steven E. Nissen, E. Murat Tuzcu, Paul Schoenhagen, B. Greg Brown, Peter Ganz, Robert A. Vogel, Tim Crowe, Gail Howard, Christopher J. Cooper, Bruce Brodie, Cindy L. Grines, and Anthony N. DeMaria
JAMA. 2004;291(9):1071-1080.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.